secwatch.observer — SEC 8-K summary
======================================

Issuer:     Applied Therapeutics, Inc. (—)
CIK:        0001697532
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0000950170-25-087352
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied Therapeutics reports mixed govorestat Phase 2/3 results; CMO departs, Bailey named
--------------------------------------------------------------------------------

- INSPIRE trial primary endpoint 10MWRT not met (p=0.7287); stat sig correlation between sorbitol reduction and CMT-HI (p<0.001) and lower limb domain (p=0.038).
- Key secondary endpoint CMT-HI showed stat sig improvement at 12 months; sorbitol reduction maintained through 24 months; MRIs suggest slowing of disease progression.
- CMO Riccardo Perfetti departed June 15; Evan Bailey appointed CMO. Bailey gets $585k base salary, 300k RSUs vesting over 4 years.
- Govorestat generally safe and well tolerated through 24 months; similar adverse event rates between active and placebo groups.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/0000950170-25-087352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1697532/000095017025087352/aplt-20250615.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-087352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer